Special Session 2: Lobular Breast Cancer Updates
Session Details
This special session will provide updates on the classification of breast cancer subtypes, emerging biomarkers with clinical relevance, ongoing debates about the role of chemotherapy, and insights from ILC-specific trials, followed by a patient advocate perspective and panel discussion.
Presentation numberSS2-02
Topic 1: Current updates on diagnostic criteria and classification of special subtypes
Anne Cs Vincent Salomon, Institut Curie, Paris, France
Presentation numberSS2-03
Topic 2: Novel biomarkers with clinical implications
Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
Presentation numberSS2-04
Topic 3: Controversies in clinical decision making—Is there still a role for chemotherapy?
Otto Metzger, Dana-Farber Cancer Institute, Chestnut Hill, MA
Presentation numberSS2-05
Topic 4: ILC-specific trials—Lessons learned and future designs
Philippe Aftimos, Institut Jules Bordet, Brussels, Belgium
Advocate
Flora Migyanka, Founder President Dynami Foundation, Plymouth, MI